$185.25 $0.91 (0.5%)

04:00 PM EST on 11/20/19

ABIOMED, Inc. (NASDAQ:ABMD)

CAPS Rating: 4 out of 5

The Company is a provider of medical devices in circulatory support and offer a continuum of care in heart recovery to acute heart failure patients.

Current Price $185.25 Mkt Cap $8.3B
Open $184.34 P/E Ratio 37.71
Prev. Close $184.34 Div. (Yield) $0.00 (0.0%)
Daily Range $184.34 - $192.01 Volume 1,155,353
52-Wk Range $155.02 - $364.31 Avg. Daily Vol. 770,046

Caps

How do you think NASDAQ:ABMD will perform against the market?

Add Stock to CAPS Watchlist

All Players

333 Outperform
38 Underperform
 

All-Star Players

95 Outperform
16 Underperform
 

Wall Street

7 Outperform
4 Underperform
 

Top NASDAQ:ABMD Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFPencils (99.86)
Submitted August 09, 2019

Despite what appear to be shorter-term headwinds, Abiomed continues to pump out cash and maintain a sterling balance sheet. The valuation is at levels not seen much (if at all) over the past five years. The company's "issues" seem correctable to me,… More

ScreenerStizBear (46.27)
Submitted June 26, 2008

I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!

Recent Community Commentary

Read the most recent pitches from players about ABMD.

Recs

0
Member Avatar MaestroFool (86.44) Submitted: 10/11/2019 1:40:38 AM : Outperform Start Price: $159.12 NASDAQ:ABMD Score: +11.55

Abiomed had been crushed this year as sales have suffered following a confusing letter from the FDA, but its heart pumps *are* safe and its tech is revolutionary. I think we'll see great things from the stock from here, the lowest valuation Abiomed has seen in years, though it may take a while. Here's something to help us wait: gross margins at 80%+. Outperform.

Recs

0
Member Avatar BretterThanMost (51.17) Submitted: 9/4/2019 8:46:45 PM : Outperform Start Price: $185.84 NASDAQ:ABMD Score: -4.99

Monopoly effect on effective heart procedures; underlying trend of increasing heart issues in the world.

Recs

1
Member Avatar TMFPencils (99.86) Submitted: 8/9/2019 1:48:40 PM : Outperform Start Price: $191.32 NASDAQ:ABMD Score: -9.56

Despite what appear to be shorter-term headwinds, Abiomed continues to pump out cash and maintain a sterling balance sheet. The valuation is at levels not seen much (if at all) over the past five years. The company's "issues" seem correctable to me, given its dominant financial position and lack of any meaningful competition. Gonna start this out on CAPS and see how it goes. :-) Outperform.

Leaderboard

Find the members with the highest scoring picks in ABMD.

Score Leader

ClaytonHP

ClaytonHP (< 20) Score: +3,035.29

The Score Leader is the player with the highest score across all their picks in ABMD.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
ClaytonHP < 20 3/27/2009 Outperform 3M $5.42 +3,317.90% +282.61% +3,035.29 0 Comment
NoWhereToGoButUp 76.79 3/25/2009 Outperform NS $5.44 +3,305.33% +294.00% +3,011.33 0 Comment
Dennyf10 51.96 6/3/2009 Outperform 1Y $6.44 +2,776.55% +237.55% +2,539.01 0 Comment
TSStechtrader 35.17 8/11/2009 Outperform NS $7.31 +2,434.20% +210.49% +2,223.71 0 Comment
dteasley4 86.23 6/8/2009 Outperform 3Y $7.30 +2,437.67% +234.54% +2,203.13 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. henrik1123 < 20 1/8/2010 Outperform 5Y $8.21 +2,155.54% +172.11% +1,983.43 0 Comment
YahooSIRIous 81.44 7/13/2009 Outperform 5Y $7.93 +2,236.07% +253.52% +1,982.55 0 Comment
PitBullCapital < 20 1/11/2010 Outperform 5Y $8.29 +2,134.62% +169.99% +1,964.63 0 Comment
QuickStoch 91.23 7/15/2009 Outperform 3W $8.06 +2,198.39% +236.65% +1,961.74 0 Comment
ezdoggy 64.07 12/29/2009 Outperform 5Y $8.80 +2,005.11% +174.93% +1,830.18 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for ABMD.